The regenerative medicine sector has long promised transformative therapeutic interventions, yet commercial viability remained elusive for decades.

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with ...

A study has found a previously known cancer-related drug can also help slow down the symptoms of Parkinson's disease, but ...

Cellexia's Cellular Renewal Cream takes a fundamentally different approach. Instead of just smoothing existing wrinkles or ...

Cervical cancer, one of the most common malignancies in women worldwide, is primarily driven by human papillomavirus (HPV) ...

Cancer cells rapidly adapt to treatments, developing resistance that makes chemotherapy less effective. Researchers used an existing anti-inflammatory drug to disrupt cancer cells’ ability to adapt by ...

Scientists identify a hidden HPV-driven cell type that could play a key role in the development of early-stage cervical ...

CGTE researchers Dr. Stelios Andreadis, center director, and Dr. Kirk Personius are lead co-authors of a paper in the October 24th edition of Nature Communications. This study describes experiments ...

Prostate cancer is one of the most common cancers and the second leading cause of cancer-related death in men worldwide. However, the mechanisms controlling the early stages of prostate cancer ...